NYSE:QGENLife Sciences
Qiagen (QGEN) Is Down 10.8% After Cutting 2026 Sales Outlook Is The Bull Case Intact?
In April 2026, Qiagen revised its full-year 2026 guidance, cutting expected net sales growth to about 1–2% CER and projecting an approximately 2% CER sales decline for the second quarter from US$534 million a year earlier.
This shift in outlook highlights how sensitive Qiagen’s results are to near-term demand trends, despite its focus on recurring diagnostic and bioinformatics revenues.
We’ll now examine how this lower 2026 net sales outlook may alter Qiagen’s previously bullish investment...